For some time, we at Oncodia have seen cancer diagnostics software used in the clinical practice, which reports false-positive somatic mutations. To demonstrate and try to quantify this, we invented…
On 30th of March, 2021 Oncodia released a scheduled update of ALTOmate to an enhanced version 1.0.1. The new version includes improvements in the read trimming capabilities, features more streamlined…
Dear Customers, We would like to inform you that effective from January 22nd 2021, Oncodia AB and LBH Advanced Bioservices AB changed the nature of collaboration regarding the distribution, service…
The development of Oncodia’s CE/IVD mutation analysis software ALTOmate is complete and we are excited to announce its commercial release. ALTOmate is the diagnostic specialist’s best friend in the mutational…
During August Oncodia raised 3.3MSEK capital in a private investment round. The company was supported by the existing owners and attracted new investors. We would like to welcome Linnéa Capital…
Following the eventful nine months spent at the premises of BASE10, on 1st of April, 2020 Oncodia’s team moved to a new location. The office of Oncodia is now at…
Oncodia has acquired the assets of ExScale Biospecimen Solutions AB, including the rights to reagent kits and software CE marked for IVD for automated extraction of DNA and RNA from…
A multidisciplinary project for personalized ovarian cancer therapy selection, termed 3D-SELECT, was granted EUR €3.47 million, of which total subsidy ~ €1.82 million, on June 25, 2019. The European consortium…
Remembering the beginning of our commercialisation journey at Uppsala University Innovation (UUI), continuing through the Uppsala Innovation Centre (UIC) Business Incubator program, today we proudly announce that Oncodia is formally…
Being a medical device company, it is essential to have a Quality Management System (QMS). With the support of external consultants, Oncodia has planned and prepared its QMS according to…